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Mitochondrial disorderMitochondrial disease involving complex II is rare among respiratory chain deﬁciencies and its genetic cause re-
mains often unknown. Twomain clinical presentations are associatedwith this biochemical defect:mitochondri-
al encephalomyopathy and susceptibility to tumors. Only one homozygous SDHBmutation has been described in
a patient with mitochondrial disorder. We report here two sisters, who presented highly different phenotypes
(neurological impairment with leukoencephalopathy vs. asymptomatic status) and harbored the same homozy-
gous SDHBmutation, suggesting reduced penetrance.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
SDHB encodes one of four structural subunits (SDHA, SDHB, SDHC,
SDHD) forming complex II (cII) of the mitochondrial respiratory chain
(MRC). cII, or succinate-ubiquinone oxidoreductase (E.C. 1.3.5.1), is
the only membrane-bound member of the tricarboxylic acid cycle,
where it functions as a succinate dehydrogenase (SDH). By coupling
this reaction to the reduction of ubiquinone to ubiquinol, cII takes part
in the MRC. At least four assembly factors (SDHAF1-4) assist the forma-
tion of the holocomplex and additional proteins are required for the
iron-sulfur clusters incorporation into cII.
Several heterozygous mutations in SDHA, SDHB, SDHC, SDHD,
SDHAF2 are susceptibility factors for developing tumors of chromafﬁn-
cells, such as paragangliomas (PGL) and phaechromocytomas, gastroin-
testinal stromal tumors and/or renal cell carcinoma [1]. On the contrary,
only a few recessivemutations in SDHA [2,3] or in SDHD [4,5], have been
reported inmitochondrial encephalomyopathywith (orwithout) cardi-
ac involvement associated with cII deﬁciency, while SDHAF1mutations
are the most common cause of mitochondrial leukoencephalopathy as-
sociated with cII deﬁciency [6,7]. The reasons determining whether cII
defects lead to neurological disease or tumor are poorly understood,; cII, mitochondrial complex II;
CSF, cerebrospinal ﬂuid; MRI,
etics, Foundation IRCCS Institute
. This is an open access article underas well the possible link between mutations in speciﬁc cII genes and
either one or the other clinical presentation.
There is only one report describing a homozygous SDHB mutation
associated with mitochondrial disease in a child affected by
leukoencephalopathy and cII deﬁciency [4]. Since no other SDHB-
related mitochondrial diseases have been reported so far, this variant
is classiﬁed as a variant of unknown signiﬁcance because its contribu-
tion to mitochondrial complex II deﬁciency has not been conﬁrmed
(MIM*185470). We describe two sisters with the same homozygous
mutation p.Asp48Val in SDHB, one presenting with severe hypotonia
and psychomotor regression with leukoencephalopathy and the other
one virtually asymptomatic.
2. Material and methods
2.1. Histochemical and biochemical analyses
Cryostatic cross sections from skeletal muscle biopsy were proc-
essed according to standard histochemical procedures. MRC complex
activities were measured using standard spectrophotometric methods
[8] in muscle homogenate and digitonin-treated skin ﬁbroblasts.
2.2. Mutational analysis
Total genomic DNA was extracted by standard methods from pe-
ripheral blood of the patients and parents. A customized gene panel
(TruSeq Custom Amplicon, Illumina) containing nuclear genes associat-
ed with cII deﬁciency (SDHA, SDHB, SDHC, SDHD, SDHAF1, SDHAF2,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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by aMiseq system (Illumina),with 100X effectivemeandepth. The gen-
erated reads were aligned to human genome assembly hg19 and the
identiﬁed variants were annotated (Variant-Studio, Illumina) and ﬁl-
tered, focusing on rare variants (minimum allele frequency b1% in
1000 Genome Project [www.1000genomes.org] and ExAc [http://exac.
broadinstitute.org] databases), causing changes potentially damaging
for the protein function (Polyphen2, SIFT). Since the pedigree was sug-
gestive for a recessive trait, we searched for genes with a homozygous
variant or two heterozygous variants. Sanger sequencing was used to
conﬁrm the mutation in the patient and the segregation in the family.
2.3. Western blot analysis
Fibroblasts were pelleted and solubilized in RIPA buffer with prote-
ase inhibitors. Lymphocytes were obtained from peripheral blood
using Lympholyte-H (Cedarlane Laboratories) and treated as described
above. 50 μg of proteins were loaded for each sample in 12% denaturing
sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Monoclonal antibodies against cII subunits SDHB and SDHA
(Mitosciences), mitochondrial porin/VDAC1 (Abcam) and GAPDH
(Millipore) were used.
3. Case reports.
The proband (P, II-4) is a girl, fourth child of healthy related -ﬁrst
cousins- parents of Pakistani origin. Family and personal history were
unremarkable. Psychomotor development was referred normal: head
control at 3 months, sitting at 6 months, walking alone at 12 months.
At 15months, a few days after a febrile illness, she presented acute psy-
chomotor regression, losing previously acquired psychomotor skills in
about a week. She was admitted to our Institute one month later. She
presented with generalized hypotonia, hyperreﬂexia, no postural con-
trol, poor voluntary movements, marked irritability with frequent cry-
ing. She did not present with seizures. Lactate and pyruvate wereFig. 1. Representative MRI images of our SDHB-mutant cases a. Brain MRI of the proband (II-4
matter and corpus callosum. Small symmetric high signal abnormalities are also present in the
restricted diffusion in the corpus callosum, thalami and, partially, in the white matter. Posterior
itations (arrow). b. Brain MRI of the asymptomatic sister II-1. Axial (i) and coronal (ii) T2-weelevated in plasma: 3327 μmol/l (normal values, nv: 580–2100)
and 151 μmol/l (nv: 55–145) respectively, and normal in CSF; 2-
ketoglutaric aciduria (557 μg/mg creatinine; nv b140) was detected.
BrainMRI showed diffuse hyperintensity of the hemispheric whitemat-
ter and corpus callosum. The subcortical U-ﬁbers are spared. Posterior
deep white matter showed evidence of rarefaction and cystic degener-
ation. There were also small symmetric hyperintensites in the thalami.
HNMR-spectroscopy demonstrated a peak of succinate and elevate lac-
tate (Fig. 1a).
Fundus oculi, electroretinogram, brainstem auditory evoked poten-
tial andmotor and sensory nerve conduction velocitieswere normal. Vi-
sual evoked potential showed central conduction abnormalities.
Electroencephalography disclosed normal background activity, with a
prevalence of slow activity in the right posterior regions. Electrocardio-
gram and echocardiogram were normal.
Informed consent for biochemical and genetic studies was obtained
from patient's parents.
All her siblings were reported in good health. The older sister (II-1),
now 11 years old, was born after uncomplicated pregnancy and deliv-
ery; her neonatal period was normal. Psychomotor development was
referred normal. She was in good health and neurological history was
negative. After the genetic analysis, she underwent a neurological ex-
amination that resulted normal. Routine exams, lactate and pyruvate
serum levels, as well as hemogasanalysis were normal. Brain MRI
showed very small symmetric lesions in the medial thalami (Fig. 1b);
HNMR-spectroscopy was normal. Because of the healthy status of the
girl, the parents did not agree on a skin or muscle biopsy.
4. Results
Histological analysis of proband's muscle biopsy showed few
hypotrophic ﬁbers, with normal lipids and glycogen content. Reduction
of cII (succinate-ubiquinone reductase) and SDH activities were docu-
mented both on muscle tissue and skin ﬁbroblasts (Fig. 2a). Complex I
activity was at the lower range of control values in muscle. Sequence). Axial T2-weighted images (i, ii) show diffuse hyperintensities in the hemispheric white
medial and posterior thalami (arrows in panel i). Diffusion-weighted images (iii, iv) show
white matter has a prevalent low signal (iv) reﬂecting partial cystic degeneration and cav-
ighted images show very small symmetric lesions in the medial thalami (arrows).
Fig. 2. Biochemical, genetic and protein studies a. Biochemical analysis ofMRC complex activities inmuscle (ms) and ﬁbroblasts (fb) from the proband. Enzyme activities, normalized for
citrate synthase activity, are expressed as percentages of the controlmean. cI, cIII, cIV: complex I, III, IV. cII: succinate-ubiquinone reductase; SDH: succinate dehydrogenase. The dotted line
indicates the lower values in the control range. b. Snapshot from IGV software of the mutation identiﬁed in the proband. SDHB is on the (−) strand thus IGV reports the reverse com-
plementarynucleotides. c. Pedigree of the family and electropherograms of the SDHB region containing the c.143ANT variant. The black symbol indicates the clinically affected subject (II-
4). d. Immunoblot analysis of total lysates obtained from ﬁbroblasts (fb) or lymphocytes (lc) of controls (Ct1 and Ct2) and SDHB-mutant subjects (II-1, II-4), detected usingα-SDHB,α-
SDHA, α-VDAC1 and α-GAPDH antibodies. The latter was used as loading control; VDAC1, an abundant mitochondrial protein, is an index of mitochondrial content in each sample.
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a panel containing nuclear genes associated with cII deﬁciency revealed
the presence of a homozygous variant in SDHB (NM_003000), c.143ANT
p.(Asp48Val) (Fig. 2b). The mutation was found to be heterozygous in
both parents (I-1, I-2: Fig. 2c); although this SDHB mutation has not
been reported in association with cancer susceptibility, we preferred
to refer parents for cancer surveillance and to expand analysis to sib-
lings. In the older sister (II-1)we found the SDHB variant in homozygos-
ity, while II-2 was heterozygous and II-3 was homozygous for the wild-
type allele (Fig. 2c). The p.Asp48Val change is predicted to be damaging
by different bioinformatics tools; moreover, the pathogenicity of this
mutationwas already experimentally validated through yeastmodeling
[4]. Finally, immunoblot analysis on proband's ﬁbroblasts showed
strongly decreased levels of SDHB, suggesting a deleterious effect of
the identiﬁed SDHB variant on protein stability; interestingly, SDHA
amount also appeared to be reduced, probably due to instability of the
assembled cII (Fig. 2d). We performed the immunoblot analysis also
on lymphocytes obtained from blood samples of the twomutant sisters
(II-1 and II-4); notably, we observed the same results in both, with a
strong reduction of SDHB and decreased levels of SDHA compared to
controls (Fig. 2d).
5. Discussion
We identiﬁed the second case of inherited biallelic SDHB mutation
associated with mitochondrial disorder; like the previous patient, she
was characterized by leukodystrophy and cII deﬁciency. Unexpectedly,
the same mutation was present also in an unaffected sister of our pro-
band. The c.143ANT variant (rs202101384) has been reported only in
South Asian subjects, butwith a very low frequency (0.036% in ExAc da-
tabase; 0 homozygotes out of 8256, in this ethnic group). Notably, both
our patients and the other described SDHB-mutant case were Asian.
Nevertheless, the pathogenicity of the p.Asp48Val amino acid changewas previously demonstrated in a yeast model [4]. In addition, the
Western blot analysis showed that SDHB level is strongly affected on
proband's ﬁbroblasts as well as in the lymphocytes from both SDHB-
mutant sisters. Decreased amount of SDHB has been observed withmu-
tations not only in SDHB but also in other SDHx genes [4,9]; however,
the extensive genetic analysis we performed, including all genes
encoding cII structural subunits and known assembly factors, detected
only the c.143A N T variant in SDHB. Moreover, all the described patients
with the c.143A N T variant (both sisters of the present paper and the
previously reported patient [4]) showed a strong decrease in SDHB
levelmaking unlikely the hypothesis that a common deleterious variant
in another SDHx gene is responsible for the SDHB reduction. All these
data strongly suggested the causative role of the identiﬁed SDHB
variant.
Despite having the same mutation, the older sister did not present
any clinical symptom and showed only minimal lesions at MRI. Howev-
er, at the protein level, the two siblings displayed the samedefect affect-
ing cII subunits. We speculate that the mutant SDHB allows a residual
activity of the cII, enough for maintaining a minimal proﬁciency of the
complex in most of the physiological conditions or during the majority
of life periods. This hypothesis is in agreement with the symptom-free
period of 15 months observed in the proband and the onset of the dis-
ease after a febrile illness; it is possible that the unaffected sister II-1
overpassed the critical periods without triggering stimuli, thus
preventing the onset of an overt clinical presentation.
Incomplete or reduced penetrance of phenotypes has been rarely as-
sociated with recessive mutations [10] and is infrequent in infantile mi-
tochondrial disorder. However, for instance, we recently described two
sisters harboring a homozygous non-sense mutation in a gene associat-
edwith anothermitochondrial leukoencephalopathy,who showed very
different clinical pictures: the older sibling developed severe motor and
cognitive impairment at an early age (after a symptom-free period)
while the second, now 16 years old, never developed neurological
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may be more prone to metabolic dysfunctions and damages than
other cerebral districts, at least in certain phases of infancy. In addition,
although common for heteroplasmic mutations in mitochondrial DNA,
incomplete penetrance has been described also for diverse
homoplasmic mutations causing even severe infantile mitochondrial
diseases [12,13].
It is not possible to deﬁne if the observed phenotypes (ranging from
leukoencephalopathy to an asymptomatic status) are strictly related to
the disease-gene or are mutation-speciﬁc; additional SDHB-mutant pa-
tients should be examined to achieve a better deﬁnition of clinical pre-
sentations, genotype/phenotype correlations and prognostic clues. After
the genetic diagnosis, treatmentwith riboﬂavin and coenzymeQ10was
started in the proband but, differently from the patient reported by
Alston and colleagues [4], the baby did not improve. Three months
later, the child presented important sweating and feeding difﬁculty
and a gavage became necessary. At neurological examination, she pre-
sented spastic tetraparesis and severe cognitive impairment.
In the past it was suggested a strict connection between cII mutated
genes and phenotypes: SDHB, SDHC, SDHD, SDHAF2 associated with
PGL4, PGL3, PGL1, PGL2 respectively; SDHA associated with Leigh syn-
drome; SDHAF1 associated with leukoencephalopathy [14]. Conversely,
recent data [4,5,15] and our ﬁndings indicate that, irrespective of the
mutated gene, recessivemutations impairing cIImay cause infantilemi-
tochondrial disease whereas germline heterozygousmutationsmay de-
termine or predispose to hereditary PGL or other tumors; a second
mutation in the other allele, occurring somatically, determines the elim-
ination of the functionally active protein and the consequent induction
of the neoplastic transformation. Thus, all genes encoding SDH subunits
or assembly factors should be assessed in cases of isolated complex II
deﬁciency in pediatric patients.6. Conclusions
Our report conﬁrms the pathogenic role of SDHBmutations in mito-
chondrial leukoencephalopathy associated with cII deﬁciency, in
addition to their established link with hereditary PGL. We thus recom-
mend to add SDHB screening in the genetic diagnostic procedure for
cII deﬁciency related-leukoencephalopathy. However, the presence of
an unaffected sister harboring the same SDHB mutation, suggests a
broad range of clinical presentations associated with this genetic defect.
This observation has important consequences in the genetic counseling,
indicating that reduced penetrance should be considered also in infan-
tile mitochondrial disorders, in particular leukoencephalopathies,
caused by nuclear gene mutations.Conﬂict of interest
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